跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,200 条关于
“BRCA2 mutation”
全部
7,200
临床试验
5,618
药物
37
机构
4
资讯
1,541
去年
Veliparib Shows Promise in BRCA-Mutated Breast Cancer: Phase II Trial Results
去年
Olaparib Provides Long-Term Survival Benefit in BRCA2-Mutated Ovarian Cancer
去年
Risk-Reducing Surgeries Significantly Improve Survival in BRCA-Positive Breast Cancer Patients
去年
BRCA2 Mechanism Reveals Why PARP Inhibitors Work in Only Some Cancer Patients
去年
Olaparib Shows Sustained Benefit in Early-Stage BRCA-Mutated Breast Cancer
去年
Niraparib and Dostarlimab Show Promise in BRCA-Mutated, ER-Positive, HER2-Negative Breast Cancer
去年
UC Davis Phase 2 Trial Reveals Circulating Tumor DNA as Key Biomarker for Personalized Prostate Cancer Treatment
去年
Study Reveals Critical Gaps in Genetic Testing and PARP Inhibitor Treatment for Advanced Prostate Cancer
去年
Blood Test Detects PARPi Resistance in Ovarian Cancer Patients with BRCA1 Mutations
2年前
NHS England Launches BRCA Testing Program for Jewish Community to Combat Cancer Risk
第 1 页,共 155 页
上一页
下一页